Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages

Bibliography

• Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 2004;91:69-136
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53
   PubMed Web of Science ®Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Xu J, Colvin JS, Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-7
   PubMed Web of Science ®Google Scholar
• Zhang X, Ibrahimi OA, Olsen SK, Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006;281:15694-700
   PubMed Web of Science ®Google Scholar
• Warzecha CC, Sato TK, Nabet B, ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009;33:591-601
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Brennan JP, Slavin JL, Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006;66:11271-8
   PubMed Web of Science ®Google Scholar
• Skroza N, Rotolo S, Ceccarelli S, Modulation of the expression of the FGFR2-IIIb and FGFR2-IIIc molecules in dermatofibroma. J Dermatol Sci 2008;51:53-7
   PubMedGoogle Scholar
• St Bernard R, Zheng L, Liu W, Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146:1145-53
   PubMedGoogle Scholar
• Finch PW, Rubin JS. Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. J Natl Cancer Inst 2006;98:812-24
   PubMed Web of Science ®Google Scholar
• Katoh M. Cancer genomics and genetics of FGFR2. Int J Oncol 2008;33:233-7
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics. Int J Mol Med 2009;23:307-11
   PubMed Web of Science ®Google Scholar
• Gartside MG, Chen H, Ibrahimi OA, Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 2009;7:41-54
   PubMed Web of Science ®Google Scholar
• Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005;105:1383-95
   PubMed Web of Science ®Google Scholar
• An Y, Cai Y, Guan Y, Inhibitory effect of small interfering RNA targeting insulin-like growth factor-I receptor in ovarian cancer OVCAR3 cells. Cancer Biother Radiopharm 2010;25:545-52
   PubMed Web of Science ®Google Scholar
• Zhang S, Tian H, Jiang Q, Suppression of epidermal growth factor receptor (EGFR) expression by small hairpin RNA inhibits the growth of human nonsmall cell lung cancers bearing wild-type and mutant EGFR. Cancer Invest 2011;29:701-8
   PubMed Web of Science ®Google Scholar
• Kummar S, Gutierrez ME, Chen A, Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer 2011;47:997-1005
   PubMed Web of Science ®Google Scholar
• Schmitz S, Kaminsky-Forrett MC, Henry S, Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 2012; published online 10 January 2012; doi:10.1093/annonc/mdr574
   Google Scholar
• Spielberger R, Stiff P, Bensinger W, Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-8
   PubMed Web of Science ®Google Scholar
• Beaven AW, Shea TC. The effect of palifermin on chemotherapy and radiation therapy-induced mucositis: a review of the current literature. Support Cancer Ther 2007;4:188-97
   PubMedGoogle Scholar
• Brizel DM, Murphy BA, Rosenthal DI, Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26:2489-96
   PubMed Web of Science ®Google Scholar
• Barasch A, Epstein J, Tilashalski K. Palifermin for management of treatment-induced oral mucositis in cancer patients. Biologicals 2009;3:111-16
   Google Scholar
• Hadari YR, Gotoh N, Kouhara H, Critical role for the docking-protein FRS2alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci USA 2001;98:8578-83
   PubMedGoogle Scholar
• Braun S, Krampert M, Bodo E, Keratinocyte growth factor protects epidermis and hair follicles from cell death induced by UV irradiation, chemotherapeutic or cytotoxic agents. J Cell Sci 2006;119:4841-9
   PubMed Web of Science ®Google Scholar
• Ray P, Devaux Y, Stolz DB, Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia. Proc Natl Acad Sci USA 2003;100:6098-103
   PubMed Web of Science ®Google Scholar
• Calautti E, Li J, Saoncella S, Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem 2005;280:32856-65
   PubMed Web of Science ®Google Scholar
• Lotti LV, Rotolo S, Francescangeli F, AKT and MAPK signaling in KGF-treated and UVB-exposed human epidermal cells. J Cell Physiol 2007;212:633-42
   PubMed Web of Science ®Google Scholar
• Zhang T, Guan H, Yang K. Keratinocyte growth factor promotes preadipocyte proliferation via an autocrine mechanism. J Cell Biochem 2010;109:737-46
   PubMedGoogle Scholar
• Chang HL, Sugimoto Y, Liu S, Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells. Anticancer Res 2009;29:3195-205
   PubMedGoogle Scholar
• Ceridono M, Belleudi F, Ceccarelli S, Torrisi MR. Tyrosine 769 of the keratinocyte growth factor receptor is required for receptor signaling but not endocytosis. Biochem Biophys Res Commun 2005;327:523-32
   PubMedGoogle Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29
   PubMed Web of Science ®Google Scholar
• Tsuboi R, Sato C, Kurita Y, Keratinocyte growth factor (FGF-7) stimulates migration and plasminogen activator activity of normal human keratinocytes. J Invest Dermatol 1993;101:49-53
   PubMed Web of Science ®Google Scholar
• Sato C, Tsuboi R, Shi CM, Comparative study of hepatocyte growth factor/scatter factor and keratinocyte growth factor effects on human keratinocytes. J Invest Dermatol 1995;104:958-63
   PubMed Web of Science ®Google Scholar
• Galiacy S, Planus E, Lepetit H, Keratinocyte growth factor promotes cell motility during alveolar epithelial repair in vitro. Exp Cell Res 2003;283:215-29
   PubMedGoogle Scholar
• Ceccarelli S, Cardinali G, Aspite N, Cortactin involvement in the keratinocyte growth factor and fibroblast growth factor 10 promotion of migration and cortical actin assembly in human keratinocytes. Exp Cell Res 2007;313:1758-77
   PubMed Web of Science ®Google Scholar
• Nguyen TN, Zang XP, Pento JT. Keratinocyte growth factor stimulates the migration and proliferation of breast cancer cells in a culture wounding model. Pharmacol Res 2002;46:179-83
   PubMedGoogle Scholar
• Niu J, Chang Z, Peng B, Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. J Biol Chem 2007;282:6001-11
   PubMedGoogle Scholar
• Wong A, Lamothe B, Lee A, FRS2alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci USA 2002;99:6684-9
   PubMed Web of Science ®Google Scholar
• Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005;16:233-47
   PubMed Web of Science ®Google Scholar
• Parrott JA, Kim G, Mosher R, Skinner MK. Expression and action of keratinocyte growth factor (KGF) in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 2000;167:77-87
   PubMedGoogle Scholar
• Yamayoshi T, Nagayasu T, Matsumoto K, Expression of keratinocyte growth factor/fibroblast growth factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis. J Pathol 2004;204:110-18
   PubMed Web of Science ®Google Scholar
• Bansal GS, Cox HC, Marsh S, Expression of keratinocyte growth factor and its receptor in human breast cancer. Br J Cancer 1997;75:1567-74
   PubMedGoogle Scholar
• Shaoul R, Eliahu L, Sher I, Elevated expression of FGF7 protein is common in human gastric diseases. Biochem Biophys Res Commun 2006;350:825-33
   PubMed Web of Science ®Google Scholar
• Planz B, Aretz HT, Wang Q, Immunolocalization of the keratinocyte growth factor in benign and neoplastic human prostate and its relation to androgen receptor. Prostate 1999;41:233-42
   PubMedGoogle Scholar
• Yoshino M, Ishiwata T, Watanabe M, Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. Int J Oncol 2007;31:721-8
   PubMed Web of Science ®Google Scholar
• Siddiqi I, Funatomi H, Kobrin MS, Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1995;215:309-15
   PubMed Web of Science ®Google Scholar
• Watanabe M, Ishiwata T, Nishigai K, Overexpression of keratinocyte growth factor in cancer cells and enterochromaffin cells in human colorectal cancer. Pathol Int 2000;50:363-72
   PubMed Web of Science ®Google Scholar
• Taniguchi F, Harada T, Sakamoto Y, Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab 2003;88:773-80
   PubMed Web of Science ®Google Scholar
• Siegfried S, Pekonen F, Nyman T Ammala M, Rutanen EM. Distinct patterns of expression of keratinocyte growth factor and its receptor in endometrial carcinoma. Cancer 1997;79:1166-71
   PubMed Web of Science ®Google Scholar
• Ishikawa A, Kudo M, Nakazawa N, Expression of keratinocyte growth factor and its receptor in human endometrial cancer in cooperation with steroid hormones. Int J Oncol 2008;32:565-74
   PubMed Web of Science ®Google Scholar
• Cho K, Ishiwata T, Uchida E, Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. Am J Pathol 2007;170:1964-74
   PubMed Web of Science ®Google Scholar
• Gillis P, Savla U, Volpert OV, Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function. J Cell Sci 1999;112:2049-57
   PubMed Web of Science ®Google Scholar
• Otte JM, Schmitz F, Banasiewicz T, Expression of keratinocyte growth factor and its receptor in colorectal cancer. Eur J Clin Invest 2000;30:222-9
   PubMedGoogle Scholar
• Hishikawa Y, Tamaru N, Ejima K, Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch Histol Cytol 2004;67:455-64
   PubMed Web of Science ®Google Scholar
• Hines MD, Allen-Hoffmann BL. Keratinocyte growth factor inhibits cross-linked envelope formation and nucleosomal fragmentation in cultured human keratinocytes. J Biol Chem 1996;271:6245-51
   PubMedGoogle Scholar
• Crescioli C, Maggi M, Luconi M, Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate 2002;50:15-26
   PubMed Web of Science ®Google Scholar
• Wildhaber BE, Yang H, Teitelbaum DH. Keratinocyte growth factor decreases total parenteral nutrition-induced apoptosis in mouse intestinal epithelium via Bcl-2. J Pediatr Surg 2003;38:92-6
   PubMed Web of Science ®Google Scholar
• Tamaru N, Hishikawa Y, Ejima K, Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab Invest 2004;84:1460-71
   PubMed Web of Science ®Google Scholar
• Kato S, Endoh H, Masuhiro Y, Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4
   PubMed Web of Science ®Google Scholar
• Thomson AA, Foster BA, Cunha GR. Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. Development 1997;124:2431-9
   PubMed Web of Science ®Google Scholar
• Werner S, Peters KG, Longaker MT, Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc Natl Acad Sci USA 1992;89:6896-900
   PubMed Web of Science ®Google Scholar
• Marchese C, Chedid M, Dirsch OR, Modulation of keratinocyte growth factor and its receptor in reepithelializing human skin. J Exp Med 1995;182:1369-76
   PubMed Web of Science ®Google Scholar
• Werner S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev 1998;9:153-65
   PubMed Web of Science ®Google Scholar
• Brauchle M, Madlener M, Wagner AD, Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease. Am J Pathol 1996;149:521-9
   PubMed Web of Science ®Google Scholar
• Finch PW, Pricolo V, Wu A, Finkelstein SD. Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease. Gastroenterology 1996;110:441-51
   PubMed Web of Science ®Google Scholar
• Chen Y, Chou K, Fuchs E, Protection of the intestinal mucosa by intraepithelial gammadelta T cells. Proc Natl Acad Sci USA 2002;99:14338-43
   PubMed Web of Science ®Google Scholar
• Steiling H, Wustefeld T, Bugnon P, Fibroblast growth factor receptor signalling is crucial for liver homeostasis and regeneration. Oncogene 2003;22:4380-8
   PubMed Web of Science ®Google Scholar
• Abo T, Nagayasu T, Hishikawa Y, Expression of keratinocyte growth factor and its receptor in rat tracheal cartilage: possible involvement in wound healing of the damaged cartilage. Acta Histochem Cytochem 2010;43:89-98
   PubMed Web of Science ®Google Scholar
• Gomperts BN, Belperio JA, Fishbein MC, Keratinocyte growth factor improves repair in the injured tracheal epithelium. Am J Respir Cell Mol Biol 2007;37:48-56
   PubMed Web of Science ®Google Scholar
• Hille A, Gruger S, Christiansen H, Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro. Radiat Environ Biophys 2010;49:261-70
   PubMed Web of Science ®Google Scholar
• Farrell CL, Bready JV, Rex KL, Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998;58:933-9
   PubMed Web of Science ®Google Scholar
• Dorr W, Reichel S, Spekl K. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol 2005a;75:99-105
   PubMed Web of Science ®Google Scholar
• Dorr W, Bassler S, Reichel S, Spekl K. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice. Int J Radiat Oncol Biol Phys 2005b;62:881-7
   PubMed Web of Science ®Google Scholar
• Kilic Y, Rajewski K, Dorr W. Effect of post-exposure administration of keratinocyte growth factor (Palifermin) on radiation effects in oral mucosa in mice. Radiat Environ Biophys 2007;46:13-19
   PubMedGoogle Scholar
• Xiao S, Nalabolu SR, Aster JC, FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998;18:84-7
   PubMed Web of Science ®Google Scholar
• Billerey C, Chopin D, Aubriot-Lorton MH, Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-9
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002;16:1446-65
   PubMed Web of Science ®Google Scholar
• Pollock PM, Gartside MG, Dejeza LC, Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen T, Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008;105:8713-17
   PubMed Web of Science ®Google Scholar
• Ricol D, Cappellen D, El Marjou A, Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999;18:7234-43
   PubMed Web of Science ®Google Scholar
• Yasumoto H, Matsubara A, Mutaguchi K, Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate 2004;61:236-42
   PubMed Web of Science ®Google Scholar
• Easton DF, Pooley KA, Dunning AM, Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Kraft P, Jacobs KB, A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4
   PubMed Web of Science ®Google Scholar
• Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001;61:3541-3
   PubMed Web of Science ®Google Scholar
• Davies H, Hunter C, Smith R, Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5
   PubMed Web of Science ®Google Scholar
• Adnane J, Gaudray P, Dionne CA, BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 1991;6:659-63
   PubMed Web of Science ®Google Scholar
• Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2004;2:643-52
   PubMedGoogle Scholar
• Werner S, Smola H, Liao X, The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 1994;266:819-22
   PubMed Web of Science ®Google Scholar
• Baskin LS, Sutherland RS, Thomson AA, Growth factors in bladder wound healing. J Urol 1997;157:2388-95
   PubMedGoogle Scholar
• Ishii H, Hattori Y, Itoh H, Preferential expression of the third immunoglobulin-like domain of K-sam product provides keratinocyte growth factor-dependent growth in carcinoma cell lines. Cancer Res 1994;54:518-22
   PubMedGoogle Scholar
• Itoh H, Hattori Y, Sakamoto H, Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Cancer Res 1994;54:3237-41
   PubMed Web of Science ®Google Scholar
• Amann T, Bataille F, Spruss T, Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol 2010;176:1433-42
   PubMedGoogle Scholar
• Savagner P, Valles AM, Jouanneau J, Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 1994;5:851-62
   PubMed Web of Science ®Google Scholar
• Carstens RP, Eaton JV, Krigman HR, Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997;15:3059-65
   PubMed Web of Science ®Google Scholar
• Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709-24
   PubMed Web of Science ®Google Scholar
• Warzecha CC, Shen S, Xing Y, Carstens RP. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol 2009;6:546-62
   PubMed Web of Science ®Google Scholar
• Decensi A, Veronesi U, Miceli R, Relationships between plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 and second breast cancer risk in a prevention trial of Fenretinide. Clin Cancer Res 2003;9:4722-9
   PubMed Web of Science ®Google Scholar
• Wang HM, Rajagopal S, Chakrabarty S. Inhibition of human colon cancer malignant cell behavior and growth by antisense epidermal growth factor receptor expression vector. Anticancer Res 1998;18:2297-300
   PubMedGoogle Scholar
• Reiss K, D'Ambrosio C, Tu X, Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res 1998;4:2647-55
   PubMedGoogle Scholar
• Wang Y, Hailey J, Williams D, Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005;4:1214-21
   PubMed Web of Science ®Google Scholar
• Xie H, Lin L, Tong L, AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One 2011;6:e21487
   Google Scholar
• Buck E, Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs 2011;20:605-21
   PubMed Web of Science ®Google Scholar
• Lee SH, Lopes de Menezes D, Vora J, In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41
   PubMed Web of Science ®Google Scholar
• Burgess T, Coxon A, Meyer S, Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-9
   PubMed Web of Science ®Google Scholar
• Yu Y, Lee P, Ke Y, A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS One 2010;5:e9072
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-73
   PubMed Web of Science ®Google Scholar
• Jun HT, Sun J, Rex K, AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13:6735-42
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Pai R, Ferrando RE, Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27:85-97
   PubMed Web of Science ®Google Scholar
• Trudel S, Stewart AK, Rom E, The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006;107:4039-46
   PubMed Web of Science ®Google Scholar
• Qing J, Du X, Chen Y, Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009;119:1216-29
   PubMed Web of Science ®Google Scholar
• Genentech. A study of the safety and pharmacokinetics of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma. United States: Food and Drug Administration, 2010. ClinicalTrials.gov identifier: NCT01122875. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01122875
   Google Scholar
• Marshall ME, Hinz TK, Kono SA, Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res 2011;17:5016-25
   PubMed Web of Science ®Google Scholar
• Five Prime Therapeutics, Inc., Worldwide Clinical Trials, LLC. Study of FP-1039 in Subjects With Endometrial Cancers. United States: Food and Drug Administration, 2010. ClinicalTrials.gov identifier: NCT01244438. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01244438
   Google Scholar
• Zang XP, Pento JT. Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metastasis 2001;18:573-80
   Web of Science ®Google Scholar
• Hackett J, Xiao Z, Zang XP, Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Res 2007;27:3801-6
   PubMed Web of Science ®Google Scholar
• Mehta M, Kesinger JW, Zang XP, Influence of novel KGFR tyrosine kinase inhibitors on KGF-mediated proliferation of breast cancer. Anticancer Res 2010;30:4883-9
   PubMed Web of Science ®Google Scholar
• Bai A, Meetze K, Vo NY, GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 2010;70:7630-9
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
   PubMed Web of Science ®Google Scholar
• Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer: from research to therapy. J Cell Sci 2007;120:1833-40
   PubMed Web of Science ®Google Scholar
• Liu CG, Calin GA, Meloon B, An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 2004;101:9740-4
   PubMed Web of Science ®Google Scholar
• Calin GA, Ferracin M, Cimmino A, A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801
   PubMed Web of Science ®Google Scholar
• Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449:682-8
   PubMed Web of Science ®Google Scholar
• Raver-Shapira N, Marciano E, Meiri E, Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26:731-43
   PubMed Web of Science ®Google Scholar
• Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007;104:15472-7
   PubMed Web of Science ®Google Scholar
• Xu N, Brodin P, Wei T, MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol 2011;131:1521-9
   PubMed Web of Science ®Google Scholar
• Lee HK, Choi YS, Park YA, Jeong S. Modulation of oncogenic transcription and alternative splicing by ß-catenin and an RNA aptamer in colon cancer cells. Cancer Res 2006;66:10560-6
   PubMed Web of Science ®Google Scholar
• Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002;62:4029-33
   PubMed Web of Science ®Google Scholar
• Rotolo S, Ceccarelli S, Romano F, Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells. PLoS One 2008;3:e2528
   PubMed Web of Science ®Google Scholar
• Ning S, Shui C, Khan WB, Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998;40:177-87
   PubMed Web of Science ®Google Scholar
• Hille A, Rave-Frank M, Pradier O, Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol 2003;79:119-28
   PubMed Web of Science ®Google Scholar
• Yasuhara T, Okamoto A, Kitagawa T, FGF7-like gene is associated with pericentric inversion of chromosome 9, and FGF7 is involved in the development of ovarian cancer. Int J Oncol 2005;26:1209-16
   PubMed Web of Science ®Google Scholar
• Taniguchi F, Harada T, Iwabe T, Aberrant expression of keratinocyte growth factor receptor in ovarian surface epithelial cells of endometrioma. Fertil Steril 2008;89:478-80
   PubMed Web of Science ®Google Scholar
• Behrens C, Lin HY, Lee JJ, Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 2008;14:6014-22
   PubMed Web of Science ®Google Scholar
• Lamont FR, Tomlinson DC, Cooper PA, Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011;104:75-82
   PubMed Web of Science ®Google Scholar
• Metzner T, Bedeir A, Held G, Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. J Invest Dermatol 2011;131:2087-95
   PubMed Web of Science ®Google Scholar
• Risuleo G, Ciacciarelli M, Castelli M, Galati G. The synthetic inhibitor of fibroblast growth factor receptor PD166866 controls negatively the growth of tumor cells in culture. J Exp Clin Cancer Res 2009;28:151
   PubMedGoogle Scholar
• Miyake M, Ishii M, Koyama N, 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther 2010;332:795-802
   PubMed Web of Science ®Google Scholar
• Zhao G, Li WY, Chen D, A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther 2011;10:2200-10
   PubMed Web of Science ®Google Scholar
• Marek L, Ware KE, Fritzsche A, Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 2009;75:196-207
   PubMed Web of Science ®Google Scholar
• Sakurai K, Yamada N, Yashiro M, A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver. Eur J Cancer 2007;43:2612-20
   PubMedGoogle Scholar
• Qiu H, Yashiro M, Zhang X, A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. Cancer Lett 2011;307:47-52
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339-45
   PubMed Web of Science ®Google Scholar
• Bello E, Colella G, Scarlato V, E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011;71:1396-405
   PubMed Web of Science ®Google Scholar
• Kim KB, Chesney J, Robinson D, Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 2011;17:7451-61
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Hackshaw A, Kaye S, Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29:3798-804
   PubMed Web of Science ®Google Scholar
• Park JW, Finn RS, Kim JS, Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17:1973-83
   PubMed Web of Science ®Google Scholar
• Yamada K, Yamamoto N, Yamada Y, Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011;17:2528-37
   PubMed Web of Science ®Google Scholar
• Kanai F, Yoshida H, Tateishi R, A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011;67:315-24
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Bui BN, Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010;46:1344-51
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Lamborn KR, Robins HI, Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neurol Oncol 2010;12:855-61
   PubMedGoogle Scholar
• Alberts SR, Fitch TR, Kim GP, Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a Phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol 2011; published online 17 March 2011; doi:10.1097/COC.0b013e3182118cdf
   Google Scholar
• Guagnano V, Furet P, Spanka C, Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011;54:7066-83
   PubMed Web of Science ®Google Scholar
• Gozgit JM, Wong MJ, Moran L, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012;11:690-9
   PubMed Web of Science ®Google Scholar
• Sun HD, Malabunga M, Tonra JR, Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrinol Metab 2007;292:E964-76
   PubMed Web of Science ®Google Scholar
• Ronca R, Benzoni P, Leali D, Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. Mol Cancer Ther 2010;9:3244-53
   PubMed Web of Science ®Google Scholar
• Li D, Wang H, Xiang JJ, Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro. Oncol Rep 2010;24:457-63
   PubMed Web of Science ®Google Scholar
• Maruyama-Takahashi K, Shimada N, Imada T, A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate 2008;68:640-50
   PubMed Web of Science ®Google Scholar